Safety aspects of SGLT2 inhibitors for treatment of heart failure | ACROSS T2D

Safety aspects of SGLT2 inhibitors for treatment of heart failure

Understanding the safety profile of a drug is essential for the treatment of patients with heart failure in order for HCPs and patients to be aware of the potential risks and benefit of a treatment option. This module details the safety profile of SGLT2 inhibitors and the effects for patients with HF.

Safety aspects of SGLT2 inhibitors for treatment of heart failure

Safety aspects of SGLT2 inhibitors for treatment of heart failure
Safety aspects of SGLT2 inhibitors for treatment of heart failure
Login or create an account to see restricted content
Safety profile of SGLT2 inhibitors in CVOTs in patients with T2D and high CV risk or eCVD
Login or create an account to see restricted content
DAPA-HF: safety profile in patients with HFrEF
Login or create an account to see restricted content
Serious AEs and prespecified AEs of interest observed in the EMPEROR-Reduced trial in patients with HFrEF
Login or create an account to see restricted content
In EMPEROR-Reduced, there was an initial dip in eGFR and later stabilisation, common in SGLT2 inhibitor treatment
Login or create an account to see restricted content
Safety aspects of SGLT2 inhibitors for treatment of heart failure
Login or create an account to see restricted content
DAPA-HF: AEs of interest by diabetes status
Login or create an account to see restricted content
No meaningful blood glucose-lowering effect in patients without type 2 diabetes with SGLT2 inhibitors
Login or create an account to see restricted content
In DAPA-HF there was an initial dip in eGFR with a later stabilisation, regardless of T2D status
Login or create an account to see restricted content
Safety aspects of SGLT2 inhibitors for treatment of heart failure
Login or create an account to see restricted content
Selected specific non-cardio–renal drug-related adverse reactions of different heart failure treatments
Login or create an account to see restricted content
What are the potential mechanisms unique to the diuretic effect of SGLT2 inhibitors?
Login or create an account to see restricted content
Electrolyte imbalances associated with therapies with diuretic effect
Login or create an account to see restricted content
Safety aspects of SGLT2 inhibitors for treatment of heart failure
Login or create an account to see restricted content
Genital infections with SGLT2 inhibitors are common, typically mild to moderate in severity and easily managed
Login or create an account to see restricted content
The safety profile of SGLT2 inhibitors is well established and includes AEs such as hypoglycaemia
Login or create an account to see restricted content
Diabetic ketoacidosis risk in patients with type 2 diabetes using SGLT2 inhibitors
Login or create an account to see restricted content
In periods of acute illness, all patients should follow “sick‑day” rules to minimise risk of complications
Login or create an account to see restricted content
Safety aspects of SGLT2 inhibitors for treatment of heart failure
Login or create an account to see restricted content
Summary